#United States #CML #Plymouth Meeting #Novartis #NCCN

NCCN Unveils Grants for Innovative CML Research Projects

The National Comprehensive Cancer Network (NCCN) recently announced funding for several groundbreaking quality improvement initiatives aimed at enhancing the lives of patients suffering from Chronic Myeloid Leukemia (CML). This initiative, overseen by the NCCN Oncology Research Program (ORP), is backed by Novartis Pharmaceuticals Corporation, highlighting the critical role of collaboration between research institutions and pharmaceutical companies in advancing oncology care.

CML is a type of cancer that affects the blood and bone marrow. Over the past 25 years, treatments for this disease, particularly the introduction of tyrosine kinase inhibitors (TKIs), have substantially improved outcomes, allowing many patients to achieve a near-normal life expectancy. Despite these advancements, experts acknowledge that the treatment landscape can still be optimized. The aim of these newly funded projects is not only to explore innovative decision-making strategies but also to improve the overall quality of life and care outcomes for people diagnosed with CML.

Newly Funded Projects

Some of the selected projects for this grant initiative include:
1. Optimizing Treatment Outcomes in Chronic Phase CML: Led by Dr. Larry D. Cripe at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, this project focuses on utilizing digital communication resources to enhance patient care and treatment adherence through a comprehensive care roadmap.
2. AGORA-CML AI-Guided Optimization: Dr. Edgar Jaimes from Memorial Sloan Kettering Cancer Center will lead this initiative, utilizing artificial intelligence to monitor treatment responses and manage potential adverse effects associated with CML therapies.
3. Evaluating CML Management Variation: Dr. Nikolai Podoltsev from Yale Cancer Center will assess variances in how CML is managed, alongside developing a pharmacist-led approach to symptom assessment that aims to enhance the delivery of care.
4. Epic-Integrated PRO-Based Tool: Under Kimberly Webster from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, this project aims to create and pilot a decision-support tool integrated with Epic systems, facilitating better monitoring of treatment-related adverse events in patients undergoing TKI therapy.

As Dr. Crystal S. Denlinger, CEO of NCCN, notes, “Taking long-term quality of life into account for patients with chronic cancers is essential.” With an increasing number of individuals living long-term with CML, shifting the focus from mere survival rates to enhancing daily experiences while on treatment has become vital.

Looking Ahead

The awarded projects are expected to be completed within two years, with the insights gleaned poised to revolutionize care for CML patients. With substantial backing from Novartis, the NCCN aims to continue fostering research and innovation that stand to significantly elevate patient care standards.

About NCCN

The National Comprehensive Cancer Network is a nonprofit alliance of top cancer centers, committed to improving cancer care quality and accessibility. Through their Clinical Practice Guidelines in Oncology (NCCN Guidelines®), they lead the way in evidence-based recommendations for cancer treatment and management, empowering both oncologists and patients to make informed decisions.

To learn more about the NCCN ORP and their funded projects, visit NCCN.org/orp.